TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Career
  • News & Media
    • Press Releases
    • Media Coverage
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Build-a-Pathway
    • FAQ
  • INVESTOR RELATIONS
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Resources
      • FAQ
      • Contact Us
    • Corporate Governance
      • Management Team
      • Medical Advisory Board
      • Scientific Advisory Board
      • Board of Directors
  • Contact

News and Media

Theralink   →  Media Room
Posted on January 6, 2021

Theralink® Technologies Issues Letter to Shareholders

DENVER, Colorado — January 6, 2021 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular pro...
Read More
Posted on November 24, 2020November 24, 2020

Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.

DENVER, Colorado — November 16, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a precision o...
Read More
Posted on September 30, 2020December 10, 2020

Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer

DENVER, Colorado — September 29, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular...
Read More
Posted on September 24, 2020December 10, 2020

Theralink® Technologies Announces Corporate Name Change

  DENVER, Colorado — September 24, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), fo...
Read More
Posted on September 15, 2020October 21, 2020

OncBioMune d/b/a Theralink® Technologies Announces Strategic Translational Research Collaboration with BioMed Valley Discoveries

Golden, Colorado – September 15th, 2020 – Theralink Technologies, Inc., a molecular profiling company (OTC: OBMP), today annou...
Read More
Posted on September 10, 2020September 10, 2020

H.C. Wainwright 22nd Annual Global Investment Conference

Mick Ruxin, M.D., President and CEO of Theralink, will present at the H.C. Wainwright 22nd Annual Global Investment Conference to...
Read More
Posted on September 10, 2020September 18, 2020

Theralink® Technologies to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

DENVER, Colorado — September 9, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Compan...
Read More
Posted on September 9, 2020

Theralink® Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory

Expects to Begin Receiving, Testing and Billing for Patient’s Breast Cancer Tumor Specimens in Q4 2020 -- DENVER, Colorado...
Read More
Posted on August 25, 2020

Theralink® Technologies to Present at the LD 500 Virtual Conference on September 1st

DENVER, Colorado — August 25, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company...
Read More
Posted on July 22, 2020December 10, 2020

Theralink® Technologies Appoints Michael Fanelli Senior Director, Biopharma Commercial Operations

  Mr. Fanelli joins the Theralink® team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring...
Read More
1 2 Next page

Categories

  • Events
  • Investor Presentation
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Issues Letter to Shareholders
  • Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
  • Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer
Copyright © 2020 Theralink. All rights reserved.
We use cookies to improve your experience on our site. If you continue the use of this site then you accept our terms of use and privacy policy.Terms & Privacy